Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients

Expert Review of Hematology

Volumn 6, Issue 6, 2013, Pages 767-784

  Isidori, Alessandro ^a   Venditti, Adriano ^b   Maurillo, Luca ^b   Buccisano, Francesco ^b   Loscocco, Federica ^a   Manduzio, Palma ^a   Sparaventi, Giovanni ^a   Amadori, Sergio ^b   Visani, Giuseppe ^a  

^a Marche Nord Hospital   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Acute myeloid leukemia; Comorbidities; Elderly patients; Intensive therapy; Low dose therapy; Novel agents; Prognostic factors; Transplantation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CLOFARABINE; CPX 351; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; LAROMUSTINE; LENALIDOMIDE; MIDOSTAURIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOPHOSMIN; QUIZARTINIB; SAPACITABINE; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; TOSEDOSTAT; UNCLASSIFIED DRUG; VALSPODAR; VINCRISTINE; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVOR; CELL VIABILITY; CLINICAL DECISION MAKING; COMORBIDITY; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOGENETICS; DISEASE FREE SURVIVAL; DONOR; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; EXTRAMEDULLARY TOXICITY; FOLLOW UP; GENE EXPRESSION; GERIATRIC ASSESSMENT; HOSPITALIZATION; HUMAN; IN VIVO STUDY; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PREMEDICATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CYTARABINE; DAUNORUBICIN; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; PURINE NUCLEOSIDES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84887977393     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.858018     Document Type: Review

References (112)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013
2. Juliusson G, Antunovic P, Derolf A et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113, 4179-4187 (2009
3. Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: An update from the Swedish Acute Leukemia Registry. Clin. Lymph. Myel. Leuk. 11(S1), S54-S59, (2011
4. Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acute myeloid leukemia. Cancer 110, 1900-1910 (2007
5. Kantarjian HM, Ravandi F, O'Brien S. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116, 4422-4429 (2010
6. Estey EH. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J. Clin. Oncol. 25, 1908-1915 (2007
7. Appelbaum F, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107,3481-3485 (2006
8. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 381(9865), 484-95 (2013
9. Luger SM. Treating the elderly patient with acute myelogenous leukemia. Hematol. Am. Soc. Hematol. Educ. Program 62-69 (2010
10. Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M. Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: Why population-based registries are needed. Blood 119(17), 3890-3899 (2012
11. Ferrara F. Treatment of unfit patients with AML: A still open clinical challenge. Clin. Lymph. Myel. Leuk. 11(1), 10-16 (2011
12. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Int. Med. 162(14), 1597-603 (2002
13. Wheatley K, Brookes CL, Howman AJ et al. United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br. J. Haematol. 145(5), 598-605 (2009
14. Grimwade D, Walker H, Harrison G et al. Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older patients with acute myeloid leukaemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98,1312-1320 (2001
15. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89, 3323-3329 (1997
16. Burnett AK, Milligan D, Goldstone A et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukemia and high risk myelodysplastic syndrome: The results of the LRF AML 14 trial. Br. J. Haematol. 145, 318:332 (2009
17. Cripte LD, Uno H, Paietta EM et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled, trial of the Eastern Cooperative Oncology Group (ECOG 3999). Blood 116(20), 4077-4085. (2010
18. Schlenk RF, Frohling S, Hartmann F et al. Phase III study of all-Trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 18, 1798-803 (2004
19. Klepin HD, Geiger AM, Tooze JA et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J. Am. Geriatr. Soc. 59(10), 1837-1846 (2011
20. Kantarjian H, O'Brien S, Cortes J et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 106, 1090-8 (2006
21. Frohling S, Schlenk RF, Kayser S et al Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 108, 3280-3288 (2006
22. Malfuson JV, Etienne A, Turlure P et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 93, 1806-1813 (2008
23. Hwang SS, Scott CB, Chang VT et al. Prediction of survival for advanced cancer patients by recursive partitioning analysis: Role of Karnofsky performance status, quality of life, and symptom distress. Cancer Invest. 22,678-687 (2004
24. Klepin HD, Geiger AM, Tooze JA et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 121(21), 4287-4294 (2013
25. Lowenberg B, Zittoun R, Kerkhofs H et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized Phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol. 7, 1268-1274 (1989
26. Wheatley K, Brookes CL, Howman AJ et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br. J. Haematol. 145, 598-605 (2009
27. Rollig C, Thiede C, Gramatzki M et al. A novel prognostic model in elderly patients with acute myeloid leukemia: Results of 909 patients entered into the prospective AML96 trial. Blood 116, 971-978 (2010
28. Burnett AK, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29(5), 487-494 (2011
29. Lowenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361, 1235-1248 (2009
30. Pautas C, Merabet F, Thomas X et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J. Clin. Oncol. 28, 808-814 (2010
31. Maurillo L, Buccisano F, Del Principe MI et al. treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr. J. Hematol. Infect. Dis. 5(1), e2013032 (2013
32. Amadori S, Breccia M, Stasi R. Acute myeloid leukemia in older patients: Conventional and new therapies. Hematology Education: The education program for the annual congress of the European Hematology Association. 7(1), 41 (2013
33. Castaigne S, Pautas C, Terré C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, Phase III study. Lancet 379, 1508-16 (2012
34. Burnett AK, Russell NH, Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J. Clin. Oncol. 30, 3924-3931 (2012
35. Amadori S, Suciu S, Stasi R et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized Phase III trial of the EORTC and GIMEMA consortium (AML-17). J. Clin. Oncol. (2013) (In Press
36. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331,896-903 (1994
37. Lowenberg B, Beck J, Graux C et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: Results of a multicenter phase 3 study. Blood 115, 2586-2591 (2010
38. Baer MR, George SL, Caligiuri MA et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin. Oncol. 26, 4934-4939 (2008
39. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE; Medical Research Council Adult Leukemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 98, 1302-1311 (2001
40. Gardin C, Turlure P, Fagot T et al. Post remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109, 5129-5135 (2007
41. Schlenk RF, Frohling S, Hartmann F et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: Results of second randomization of the AML HD98-B treatment trial. Leukemia 20,748-750 (2006
42. Poloni A, Capelli D, Trappolini S et al. Low-dose Gemtuzumab ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: A pilot study. Br. J. Haematol. 150(1), 119-121 (2010
43. Cascavilla N, D'Arena G, Greco MM, Melillo L, Merla E, Carella AM. Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia. Br. J. Haematol. 142(5), 852-853 (2008
44. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361(11), 1058-1066 (2009
45. Ungewickell A, Medeiros BC. Novel gents in acute myeloid leukemia. Int. J. Hematol. 96, 178-185 (2012
46. Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3), 453-474 (2010
47. Burnett A, Russell N, Kell J et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J. Clin. Oncol. 28, 2389-2395 (2010
48. Kantarjian HM, Erba HP, Claxton D et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J. Clin. Oncol. 28(4), 549-555 (2010
49. Burnett AK, Russell NH, Hunter AE et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122(8), 1384-1394 (2013
50. Faderl S, Ravandi F, Huang X et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112,1638-1645 (2008
51. Faderl S, Ravandi F, Huang X et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18), 4471-4477 (2012
52. Chapuis N, Tamburini J, Green AS et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 24,1686-1699 (2010
53. Chapuis N, Tamburini J, Green AS et al. Dual inhibition of PI3K and mTORC1/ 2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res. 16, 5424-5435 (2010
54. Amadori S, Stasi R, Martelli AM et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a Phase II GIMEMA study (AML-1107). Br. J. Haematol. 156, 205-212 (2011
55. Thomas X. DNA methyltransferase inhibitors in acute myeloid leukemia: Discovery, design and first therapeutic experiences. Expert Opin. Drug Discov. 7, 1039-1045 (2012
56. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223-232 (2009
57. Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 28(4), 562-569 (2010
58. Maurillo L, Venditti A, Spagnoli A et al. Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian Compassionate Program. Cancer 118(4), 1014-1022 (2012
59. Pollyea DA, Zehnder J, Coutre S et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica 98(4), 591-596 (2013
60. Ravandi F, Alattar ML, Grunwald MR et al. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23), 4655-4662 (2013
61. Kantarjian HM, Thomas XG, Dmoszynska A et al. Multicenter, randomized, open-label, Phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 30(21), 2670-2677 (2012
62. Lübbert M, Rüter BH, Claus R et al. A multicenter Phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 97(3), 393-3401 (2012
63. Quintas-Cardama A, Ravandi F, Liu-Dumlao T et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 120, 4840-4845 (2012
64. Ritchie EK, Feldman EJ, Christos PJ et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk. Lymphoma (2013) (Epub ahead of print
65. Passweg JR, Pabst T, Blum S et al. Azacytidine for acute myeloid leukemia in elderly or frail patients: A Phase II trial (SAKK 30/07). Leuk. Lymphoma PMID: 23547838 (2013) (Epub ahead of print
66. Blum W, Klisovic RB, Becker H et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J. Clin. Oncol. 28(33), 4919-4925 (2010
67. Fehniger TA, Uy GL, Trinkaus K et al. A Phase II study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 117(6), 1828-1833 (2011
68. Ramsingh G, Westervelt P, Cashen AF et al. A Phase I study of concomitant high-dose lenalidomide and 5-Azacitidine induction in the treatment of AML. Leukemia 27(3), 725-728 (2013
69. Isidori A, Ferrara F, Di Raimondo F et al. Low-dose lenalidomide plus low-dose cytarabine induce complete remission that can be predicted by genetic profiling in very elderly acute myeloid leukemia patients. Haematologica 98(s1), 246 (2013
70. Löwenberg B, Morgan G, Ossenkoppele GJ et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 28(28), 4333-4338 (2010
71. Cortes J, Feldman E, Yee K et al. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): A randomised open-label Phase II study. Lancet Oncol. 14(4), 354-362 (2013
72. Schiller GJ, O'Brien SM, Pigneux A et al. Single-Agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J. Clin. Oncol. 28(5), 815-821 (2010
73. Deisseroth A, Farrell A, Justice R et al. Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia. Blood 14;115(2), 430. (2010
74. Kantarjian H, Faderl S, Garcia-Manero G et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: A randomised Phase II study. Lancet Oncol. 13(11), 1096-1104 (2012
75. Lancet JE, Cortes J, Kovacsovics T et al. A comparison of CR versus CRi response following CPX-351 treatment of newly diagnosed AML in elderly patients (pts). J. Clin. Oncol. ASCO abstract 6601 (2012
76. Cahn JY, Labopin m, Mandelli F et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group. Blood 85, 575-579 (1995
77. Gorin NC, Labopin M, Pichard P et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukemia in patients over 60 years of age: Importance of the source of stem cells. Br. J. Haematol. 110, 887-893 (2000
78. Herr AL, Labopin M, Blaise D et al. Acute Leukemia Working Party or the European Group for Blood and Marrow Transplantation. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 21, 129-135 (2007
79. Cancer and Leukemia Group B 8461, Farag SS, Archer KJ et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-Term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108(1), 63-73 (2006
80. Frohling S, Schlenk RF, Kayser S et al Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 108,3280-88 (2006
81. Cornelissen JJ, van Putten WLJ, Verdonck LF et al. Results of a HOVON/ SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: Benefits for whom? Blood 109, 3658-3666 (2007
82. Jourdan E, Boiron JM, Dastugue N et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent to-Treat long-Term analysis of the BGMT experience. J. Clin. Oncol. 23, 7676-7684 (2005
83. Cahn JY, Labopin M, Schattenberg A et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia. 11, 416-419 (1997
84. Estey E, de Lima M, Tibes R et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109(4), 1395-1400 (2007
85. Ustun C, Lazarus HM, Weisdorf D. To transplant or not: A dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. 1-9 (2013
86. Farag SS, Maharry K, Zhang MJ. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol. Blood Marrow Transplant. 17(12), 1796-803 (2011
87. Kurosawa S, Yamaguchi T, Uchida N et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol. Blood Marrow Transplant. 17, 401-411 (2011
88. Mohty M, de Lavallade H, El-Cheikh J et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: Long term results of a donor versus no donor comparison. Leukemia 23(1), 194-196 (2009
89. McClune BL, Weisdorf DJ, Pedersen TL et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J. Clin. Oncol. 28(11), 1878-1887 (2010
90. Koreth J, Aldridge J, Kim HT et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: Hematologic malignancy outcomes are not impaired in advanced age. Biol. Blood Marrow Transplant. 16(6), 792-800 (2010
91. Gyurkocza B, Storb R, Storer BE et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J. Clin. Oncol. 28(17), 2859-2867 (2010
92. Chevallier P, Szydlo RM, Blaise D et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: A report from the Sfgm-Tc. Biol. Blood Marrow Transplant. 18, 289-294 (2012
93. Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19(12), 2304-2312 (2005
94. Tauro S, Craddock C, Peggs K et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-Term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 23(36), 9387-9393 (2005
95. Valcarcel D, Martino R, Caballero D et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J. Clin. Oncol. 26(4), 577-584 (2008
96. Devine S, Owzar K, Blum W et al A Phase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: Results from CALGB 100103/BMT CTN 0502. Blood Abstract 230 (2012
97. De Lima M, Anagnostopoulos A, Munsell M et al. Non-Ablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-Term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3), 865-872 (2004
98. Grimwade D, Hills RK, Moorman AV et al. National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116, 354-365 (2010
99. Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13), 4325-4336 (2002
100. Breems DA, Van Putten WLJ, De Greef GE et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J. Clin. Oncol. 26, 4791-4797 (2008
101. Perrot A, Luquet I, Pigneux A et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: A GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 118, 679-685 (2011
102. Schlenk RF, Dohner K, Krauter J et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358(18), 1909-1918 (2008
103. Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3), 453-474 (2010
104. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic. Dis. 40 (5), 373-383 (1987
105. Sorror ML, Maris MB, Storer B et al. Comparing morbidity e mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplant comorbidities. Blood 104 (4), 961-968 (2004
106. Sorror ML, Maris M, Storer B et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukaemia. J. Clin. Oncol. 23(16), 3819-3829 (2005
107. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106(15), 2912-2919 (2005
108. Sorror ML, Sandmaier BM, Storer BE et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia and myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 25 (27), 4246-4254 (2007
109. Majhail NS, Brunstein CG, Tomblyn M et al. Reduced-intensity allogeneic transplant in patients older than 55 years: Unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol. Blood. Marrow. Transplant. 14, 282-289 (2008
110. De Latour RP, Brunstein CG, Porcher R et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol. Blood Marrow Transplant. 19(9), 1355-1360 (2013
111. Kurokawa T, Ishiyama K, Ozaki J et al. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: Analysis of 66 cases at a single Japanese center. Int. J. Hematol. 91(4), 661-669 (2010
112. Ciurea SO, Saliba R, Rondon G et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone. Marrow. Transplant. 45(3), 429-436 (2010